The North America Synthetic Opioids Market to Be Backed By Stellar Innovations

The North America Synthetic Opioids Market is expected to grow on a healthy note in the subsequent decade. With value-based care picking up, close to 15% of the entire population is under its umbrella as of now. Programs like "Online Bachelor's Degree in General Studies with a Concentration in Healthcare" is being floated, which could aid professionals to lead in the value-based care strategies. In other words, the future belongs to professionals bringing conventional skills in communication, care, and leadership with new-fangled skills in analytics and technology. So, "being value-based" would hold value in the healthcare vertical in the future.

Demand for synthetic opioids continues to witness a decline in North America. According to a new research from Persistence Market Research, the US$ 75 billion synthetic opioids market will grow at a sluggish 2.4% during the period 2016-2024.

Rising concerns about the addictive nature of opioids, combined with drug abuse has led to declining sales. According to the Centers for Disease Control and Prevention (CDC) around 33,000 Americans died from opioid overdose in 2015. The agency also reported that almost half of non-cancer patients who have been prescribed opioids for a month are still dependent on the pills a year later. Further, side effects of synthetic opioids, such as reduce, urinary difficulties, appetite loss, and spells of dizziness are also influencing sales negatively.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/15898

According to Persistence Market Research, introduction of non-abuse opioid drugs and drug exclusivity for branded options are the opportunities for pharmaceutical companies.

Company Profiles:
Purdue Pharma LP
Pfizer Inc.
Janssen Pharmaceuticals, Inc.
Teva Pharmaceuticals
Endo International plc
West-Ward Pharmaceuticals (Hikma's US subsidiary)
Mallinckrodt Pharmaceuticals plc
Mylan N.V.
Impax Laboratories, Inc
Indivior Plc.
Others.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/15898

Key Trends

Leading pharmaceutical companies are partnering with pain management service providers to boost sales.

Focus on developing non-addictive variants is growing, with leading players altering their packaging and drug formulation.

Pharmaceutical companies are promoting their novel products to cut down competition from generic manufacturers.

The Drug Enforcement Administration's plan to reduce the amount of Schedule II opioid pain medication manufactured in the U.S. by 25% can significantly impact sales in foreseeable future.
Persistence Market Research's study on the North
America synthetic opioids market revealed that only 18% of opioids are obtained from licensed physicians. The report also found that increasing government regulations and DEA cuts can reduce unauthorized access.

By product type, the report has segmented the market into synthetic opioids and semi-synthetic opioids. Semi-synthetic opioids continue to witness heavy demand, accounting for nearly 92% value share in 2016. By sales, highest-selling semi-synthetic opioids are hydrocodone, oxycodone, and buprenorphine.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/15898

Pain management remains the dominant application of synthetic opioids, accounting for over 90% revenue share of the market in 2016. Valued at over US$ 67 billion in 2016, use of synthetic opioids for pain management is expected to grow at 2.3% CAGR through 2024.

Retail outlets remain the dominant application segment for synthetic opioids, accounting for nearly 66% revenue share in 2016. Availability of synthetic opioids in retail outlets will continue to influence sales. By 2020, US$ 55 Bn worth of synthetic opioids will be sold through retail outlets in North America.

The U.S. remains at the forefront of global demand for opioids; unsurprisingly, it dominates the North America synthetic opioids market. Canada's revenue share - 9.9% in 2016 - is projected to reach 10.6% by 2026.

Access Related Reports-

Leadless Pacing System Market: https://www.persistencemarketresearch.com/market-research/leadless-pacing-system-market.asp

Duchenne Muscular Dystrophy Treatment Market: https://www.persistencemarketresearch.com/market-research/duchenne-muscular-dystrophy-treatment-market.asp

About Us
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.